Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study
Abstract Background In a large randomized controlled trial (PARADIGM-HF), ARNI has been shown to significantly reduce cardiovascular mortality and hospitalization for patients with reduced ejection fraction in heart failure. This study analyzed the efficacy and safety of ARNI on the basis of various...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-07-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-023-03374-w |
| _version_ | 1797779043625467904 |
|---|---|
| author | Xiaobo Wang Jun Pu Guixia Wang Hui Xu Liming Liu Zhen Li Ruijie Qin Xuemei Zhao Ming Li Zedong Hao Houxiang Hu |
| author_facet | Xiaobo Wang Jun Pu Guixia Wang Hui Xu Liming Liu Zhen Li Ruijie Qin Xuemei Zhao Ming Li Zedong Hao Houxiang Hu |
| author_sort | Xiaobo Wang |
| collection | DOAJ |
| description | Abstract Background In a large randomized controlled trial (PARADIGM-HF), ARNI has been shown to significantly reduce cardiovascular mortality and hospitalization for patients with reduced ejection fraction in heart failure. This study analyzed the efficacy and safety of ARNI on the basis of various types of heart failure patients in southwestern Sichuan Province. Methods This study included patients with heart failure who were treated at the Affiliated Hospital of North Sichuan Medical College from July 2017 to June 2021. This study analyzed the efficacy and safety of ARNI in the treatment of heart failure, and analyzed the risk factors for readmission after ARNI treatment. Results After propensity score matching, a total of 778 patients were included in the study. The readmission rate for heart failure in patients treated with ARNI (8.7%) was significantly lower than that in the standard treatment group (14.5%) (P = 0.023). Both the proportion of patients with increased LVEF and with decreased LVEF were higher in the ARNI treatment group than in the conventional therapy group. Compared with receiving standard medical treatment, combined ARNI treatment resulted in a greater reduction in SBP (-10.00, 95%CI: -24.00-1.50 vs. -7.00, 95%CI: -20.00-4.14; P = 0.016) in HF patients. Combination ARNI therapy did not increase the risk of adverse events. The study found that age (> 65 vs. ≤65 years) (OR = 4.038, 95%CI: 1.360-13.641, P = 0.013) and HFrEF (OR = 3.162, 95%CI: 1.028–9.724, P = 0.045) were independent predictors of readmission in HF patients treated with ARNI. Conclusion Patients with heart failure treated with ARNI can improve clinical symptoms and reduce the risk of readmitted hospital admission. Age > ~ 65 years and HFrEF were independent predictors of readmission in HF patients treated in ARNI group. |
| first_indexed | 2024-03-12T23:26:02Z |
| format | Article |
| id | doaj.art-3deb5bef2c9a4f2eb9467a1bd64ebe39 |
| institution | Directory Open Access Journal |
| issn | 1471-2261 |
| language | English |
| last_indexed | 2024-03-12T23:26:02Z |
| publishDate | 2023-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj.art-3deb5bef2c9a4f2eb9467a1bd64ebe392023-07-16T11:08:59ZengBMCBMC Cardiovascular Disorders1471-22612023-07-012311810.1186/s12872-023-03374-wEfficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective studyXiaobo Wang0Jun Pu1Guixia Wang2Hui Xu3Liming Liu4Zhen Li5Ruijie Qin6Xuemei Zhao7Ming Li8Zedong Hao9Houxiang Hu10Department of Cardiology, Affiliated Hospital of North Sichuan Medical CollegeDepartment of Cardiology, Affiliated Hospital of North Sichuan Medical CollegeInfectious Department, The Third People’s Hospital of ChengduDepartment of Cardiology, Affiliated Hospital of North Sichuan Medical CollegeDepartment of Gerontology, Affiliated Hospital of North Sichuan Medical CollegeUndergraduate in clinical medicine, North Sichuan Medical CollegeUndergraduate in clinical medicine, North Sichuan Medical CollegeDepartment of Cardiology, Affiliated Hospital of North Sichuan Medical CollegeShanghai Synyi Medical Technology Co., LtdShanghai Synyi Medical Technology Co., LtdDepartment of Cardiology, Affiliated Hospital of North Sichuan Medical CollegeAbstract Background In a large randomized controlled trial (PARADIGM-HF), ARNI has been shown to significantly reduce cardiovascular mortality and hospitalization for patients with reduced ejection fraction in heart failure. This study analyzed the efficacy and safety of ARNI on the basis of various types of heart failure patients in southwestern Sichuan Province. Methods This study included patients with heart failure who were treated at the Affiliated Hospital of North Sichuan Medical College from July 2017 to June 2021. This study analyzed the efficacy and safety of ARNI in the treatment of heart failure, and analyzed the risk factors for readmission after ARNI treatment. Results After propensity score matching, a total of 778 patients were included in the study. The readmission rate for heart failure in patients treated with ARNI (8.7%) was significantly lower than that in the standard treatment group (14.5%) (P = 0.023). Both the proportion of patients with increased LVEF and with decreased LVEF were higher in the ARNI treatment group than in the conventional therapy group. Compared with receiving standard medical treatment, combined ARNI treatment resulted in a greater reduction in SBP (-10.00, 95%CI: -24.00-1.50 vs. -7.00, 95%CI: -20.00-4.14; P = 0.016) in HF patients. Combination ARNI therapy did not increase the risk of adverse events. The study found that age (> 65 vs. ≤65 years) (OR = 4.038, 95%CI: 1.360-13.641, P = 0.013) and HFrEF (OR = 3.162, 95%CI: 1.028–9.724, P = 0.045) were independent predictors of readmission in HF patients treated with ARNI. Conclusion Patients with heart failure treated with ARNI can improve clinical symptoms and reduce the risk of readmitted hospital admission. Age > ~ 65 years and HFrEF were independent predictors of readmission in HF patients treated in ARNI group.https://doi.org/10.1186/s12872-023-03374-wStandard treatmentAngiotensin receptor neprilysin inhibitionHeart failureReal-world retrospective study |
| spellingShingle | Xiaobo Wang Jun Pu Guixia Wang Hui Xu Liming Liu Zhen Li Ruijie Qin Xuemei Zhao Ming Li Zedong Hao Houxiang Hu Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study BMC Cardiovascular Disorders Standard treatment Angiotensin receptor neprilysin inhibition Heart failure Real-world retrospective study |
| title | Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study |
| title_full | Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study |
| title_fullStr | Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study |
| title_full_unstemmed | Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study |
| title_short | Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study |
| title_sort | efficacy and safety analysis of angiotensin receptor neprilysin inhibition arni in patients with heart failure a real world retrospective study |
| topic | Standard treatment Angiotensin receptor neprilysin inhibition Heart failure Real-world retrospective study |
| url | https://doi.org/10.1186/s12872-023-03374-w |
| work_keys_str_mv | AT xiaobowang efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT junpu efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT guixiawang efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT huixu efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT limingliu efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT zhenli efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT ruijieqin efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT xuemeizhao efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT mingli efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT zedonghao efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy AT houxianghu efficacyandsafetyanalysisofangiotensinreceptorneprilysininhibitionarniinpatientswithheartfailurearealworldretrospectivestudy |